HC Wainwright Reiterates Buy Rating for Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Truist Financial cut their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Barclays raised their price objective on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Wells Fargo & Company lowered their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. Finally, Jefferies Financial Group cut their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Price Performance

NASDAQ:SGMO opened at $1.13 on Monday. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The company has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $1.33. The company has a market cap of $235.77 million, a price-to-earnings ratio of -1.51 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to analysts’ expectations of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the previous year, the firm posted ($0.34) EPS. On average, analysts expect that Sangamo Therapeutics will post -0.47 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SGMO. Meritage Portfolio Management raised its stake in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 6,740 shares during the last quarter. Shelton Wealth Management LLC purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter worth approximately $29,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 38,850 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Sangamo Therapeutics by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after buying an additional 57,125 shares during the period. Finally, Sageworth Trust Co purchased a new position in Sangamo Therapeutics during the 4th quarter worth $61,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.